Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYRNASDAQ:BLUENASDAQ:ENGNNASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRAtyr PHARMA$3.40+3.8%$3.35$1.42▼$4.66$301.68M0.951.32 million shs728,912 shsBLUEbluebird bio$4.07-3.0%$4.29$3.56▼$28.60$39.80M0.41367,998 shs44,676 shsENGNenGene$4.05+1.4%$4.80$3.50▼$16.62$205.44M-0.38131,485 shs68,501 shsVYGRVoyager Therapeutics$3.57+1.0%$3.63$2.75▼$9.55$197.74M1.02449,571 shs98,009 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRAtyr PHARMA-2.39%-0.30%+4.47%-5.49%+326,999,900.00%BLUEbluebird bio+0.72%+7.44%+2.70%-46.01%-77.30%ENGNenGene+2.57%0.00%-7.21%-42.42%-74.26%VYGRVoyager Therapeutics+1.73%+9.97%-3.29%-36.96%-53.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATYRAtyr PHARMA2.3742 of 5 stars3.61.00.00.02.03.30.6BLUEbluebird bio3.0006 of 5 stars3.14.00.00.02.22.51.3ENGNenGene3.3908 of 5 stars4.53.00.00.01.92.50.6VYGRVoyager Therapeutics4.5828 of 5 stars4.61.00.04.62.21.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATYRAtyr PHARMA 3.14Buy$18.60447.86% UpsideBLUEbluebird bio 2.25Hold$44.60997.17% UpsideENGNenGene 3.00Buy$23.29475.67% UpsideVYGRVoyager Therapeutics 3.11Buy$13.97291.76% UpsideCurrent Analyst Ratings BreakdownLatest BLUE, VYGR, ENGN, and ATYR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025ENGNenGeneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$18.00 ➝ $18.004/8/2025VYGRVoyager TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/31/2025BLUEbluebird bioBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $8.003/14/2025ATYRAtyr PHARMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.003/13/2025VYGRVoyager TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.003/13/2025VYGRVoyager TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/12/2025VYGRVoyager TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$12.00 ➝ $10.003/12/2025VYGRVoyager TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/12/2025VYGRVoyager TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/11/2025ENGNenGeneMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$37.00 ➝ $34.003/11/2025ENGNenGeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRAtyr PHARMA$235K1,283.73N/AN/A$1.54 per share2.20BLUEbluebird bio$83.81M0.47N/AN/A$35.59 per share0.11ENGNenGeneN/AN/AN/AN/A$6.17 per shareN/AVYGRVoyager Therapeutics$80.00M2.46$2.53 per share1.41$5.37 per share0.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRAtyr PHARMA-$50.39M-$0.87N/AN/AN/AN/A-79.44%-59.16%5/1/2025 (Estimated)BLUEbluebird bio-$211.91M-$45.54N/AN/AN/A-565.74%-322.46%-53.17%5/7/2025 (Estimated)ENGNenGene-$55.14M-$1.52N/AN/AN/AN/A-16.69%-14.27%6/10/2025 (Estimated)VYGRVoyager Therapeutics$132.33M-$1.135.04N/AN/A15.80%8.33%6.15%5/12/2025 (Estimated)Latest BLUE, VYGR, ENGN, and ATYR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025VYGRVoyager Therapeutics-$0.35N/AN/AN/A$13.55 millionN/A5/7/2025Q1 2025BLUEbluebird bio-$2.42N/AN/AN/A$39.03 millionN/A5/1/2025Q1 2025ATYRAtyr PHARMA-$0.19N/AN/AN/AN/AN/A3/13/2025Q4 2024ATYRAtyr PHARMA-$0.23-$0.18+$0.05-$0.18$0.02 millionN/A3/11/2025Q4 2024VYGRVoyager Therapeutics-$0.35-$0.59-$0.24-$0.59$16.58 million$4.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATYRAtyr PHARMAN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/AENGNenGene$1.5839.09%N/AN/A N/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRAtyr PHARMA0.025.415.41BLUEbluebird bio0.370.510.33ENGNenGene0.0816.8716.87VYGRVoyager TherapeuticsN/A8.458.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRAtyr PHARMA61.72%BLUEbluebird bio87.43%ENGNenGene64.16%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipATYRAtyr PHARMA3.70%BLUEbluebird bio1.40%ENGNenGene13.70%VYGRVoyager Therapeutics4.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRAtyr PHARMA5388.86 million80.84 millionOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableENGNenGene3150.98 million38.16 millionN/AVYGRVoyager Therapeutics10055.31 million52.15 millionOptionableBLUE, VYGR, ENGN, and ATYR HeadlinesRecent News About These CompaniesVoyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual MeetingApril 28 at 4:30 PM | globenewswire.comBrokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) PT at $13.97April 24, 2025 | americanbankingnews.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of "Buy" from BrokeragesApril 22, 2025 | marketbeat.comVoyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...April 21, 2025 | finance.yahoo.comFY2026 Earnings Forecast for VYGR Issued By Leerink PartnrsApril 20, 2025 | marketbeat.comResearch Analysts Offer Predictions for VYGR FY2026 EarningsApril 20, 2025 | americanbankingnews.com7 Analysts Assess Voyager Therapeutics: What You Need To KnowApril 10, 2025 | nasdaq.comVoyager Therapeutics (NASDAQ:VYGR) Receives "Buy" Rating from HC WainwrightApril 10, 2025 | marketbeat.comVoyager updates on Alzheimer’s programs ‘compelling,’ says H.C. WainwrightApril 9, 2025 | markets.businessinsider.comADAR1 Capital Management LLC Acquires 86,158 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)April 9, 2025 | marketbeat.comTD Cowen Keeps Their Buy Rating on Voyager Therapeutics (VYGR)April 8, 2025 | markets.businessinsider.com2VYGR : 7 Analysts Assess Voyager Therapeutics: What You Need To KnowApril 8, 2025 | benzinga.comRaymond James Financial Inc. Takes Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)April 7, 2025 | marketbeat.comAlfred Sandrock Sells 10,885 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) StockApril 6, 2025 | insidertrades.comInsider Selling: Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Sells 10,885 Shares of StockApril 6, 2025 | marketbeat.comPrudential Financial Inc. Sells 82,100 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)April 6, 2025 | marketbeat.comVoyager Therapeutics Presents Promising Tau-Targeting Gene Therapy And Antibody Data At AD/PD 2025April 2, 2025 | nasdaq.comVoyager Therapeutics, Inc.: Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD 2025March 31, 2025 | finanznachrichten.deVoyager Therapeutics announces new data from two preclinical programsMarch 31, 2025 | markets.businessinsider.comVoyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025March 31, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGRMarch 19, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer StockBy Jea Yu | April 21, 2025View AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer StockBig Blue's Big Shift: IBM's Turnaround Bet on Cloud and AIBy Jeffrey Neal Johnson | April 7, 2025View Big Blue's Big Shift: IBM's Turnaround Bet on Cloud and AIHidden Gems: 3 Quiet Stocks With Loud PotentialBy Nathan Reiff | April 23, 2025View Hidden Gems: 3 Quiet Stocks With Loud Potential Microsoft: A Blend of Growth and Value Amid Tariff ConcernsBy Chris Markoch | April 15, 2025View Microsoft: A Blend of Growth and Value Amid Tariff ConcernsBLUE, VYGR, ENGN, and ATYR Company DescriptionsAtyr PHARMA NASDAQ:ATYR$3.40 +0.13 (+3.82%) As of 02:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.bluebird bio NASDAQ:BLUE$4.07 -0.13 (-2.98%) As of 02:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.enGene NASDAQ:ENGN$4.04 +0.06 (+1.38%) As of 02:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Voyager Therapeutics NASDAQ:VYGR$3.56 +0.04 (+0.99%) As of 02:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
